IBCN 2023: Long Term Recurrence Risk, Metastatic Potential, and Length of...
(UroToday.com) Historically, very few patients with Ta low grade (LG) bladder cancer (BC) are at risk of developing metastases or dying of BC. However, long term follow-up data are scant and length of...
View ArticleIBCN 2023: Transurethral Resections of Bladder Tumor Quality Criteria and...
(UroToday.com) Transurethral resection of the bladder tumors (TURBT) is essential in the management of bladder cancer (BC). The objective of this study was to compare TURBT quality criteria and to...
View ArticleIBCN 2023: SURE-01: Interim Results of a Phase 2 Study of Neoadjuvant...
(UroToday.com) For patients with muscle invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy, there is no standard-of-care neoadjuvant therapy. SG is an...
View ArticleIBCN 2023: An Holistic and Intergrated Approach for Investigating the...
(UroToday.com) Bladder cancer (BC) is the 10th most common cancer worldwide with an estimated 570,000+ people being diagnosed in 2020. Communities of bacteria exist in both normal and cancerous tissues...
View ArticleIBCN 2023: Evaluation of Molecular Residual Disease by Urinary Comprehensive...
(UroToday.com) BCG-unresponsive (BU) non-muscle invasive bladder cancer (NMIBC) is associated with high rates of recurrence and progression. Methods to assess recurrence risk and monitor therapeutic...
View ArticleIBCN 2023: Field Cancerization Impacts Tumor Development, T-Cell Exhaustion...
(UroToday.com) Field cancerization, describing areas of normal tissue affected by mutated clones, may affect treatment response and outcome in bladder cancer. High urinary tumor DNA (utDNA) levels in...
View ArticleIBCN 2023: Patient-Derived Organoids Identify Tailored Therapeutic Options...
(UroToday.com) Sarcomatoid Urothelial Bladder Cancer (SARC) is a rare and aggressive histological subtype of bladder cancer. Here, we established the first long-term 3D organoid-like model derived from...
View ArticleIBCN 2023: Exploring the Impact of Microbiome in the Response of Combined...
(UroToday.com) Radiation therapy (RT) is a promising bladder-sparing option for muscle invasive bladder cancer (MIBC) treatment, yet 30% of patients do not respond and half later die of metastasis....
View ArticleIBCN 2023: Meta-Analysis of GWAS Data from Diverse Populations for Bladder...
(UroToday.com) To date, the largest genome-wide association study (GWAS) of bladder cancer susceptibility (Koutros, Eur Urol, 2023, NCI-meta) involved a meta-analysis of 13,790 individuals with bladder...
View ArticleIBCN 2023: Alignment Of Molecular Subtypes Across Multiple Bladder Cancer...
(UroToday.com) Guideline-recommended treatment for muscle-invasive bladder cancer (MIBC) patients includes cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). There is a...
View ArticleIBCN 2023: Gene Expression-Based Classification of Urothelial Carcinoma For...
(UroToday.com) Transcriptomic subtype prediction of urothelial carcinomas can be affected by the choice of expression platform, cohort composition, data preprocessing, and tumor purity. To address...
View ArticleIBCN 2023: Added Value of ctDNA Testing For Identifying FGFR3 Alterations In...
(UroToday.com) Fibroblast growth factor receptor (FGFR) inhibitors (e.g., erdafitinib) are increasingly important in the management of FGFR-altered metastatic urothelial carcinoma (mUC). Archival...
View ArticleIBCN 2023: Simulating The Effects of Molecular Urine Markers In Follow-Up Of...
(UroToday.com) There are numerous urine markers for diagnosis and follow-up of patients with bladder cancer which have been developed and studied in the past. However, the clinical impact of urine...
View ArticleIBCN 2023: Molecular Signatures Predict GEMDOCE Responses for...
Intravesical combination chemotherapy (gemcitabine and docetaxel [GEMDOCE]) is commonly used to treat patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). However, potential...
View ArticleIBCN 2023: A Composite Biomarker Approach to Spare Neoadjuvant Chemotherapy...
Clinical guidelines recommend neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for the management of muscle-invasive bladder cancer (MIBC), despite treatment-related toxicity and a...
View ArticleIBCN 2023: Urinary Comprehensive Genomic Profiling Predicts Urothelial Cancer...
(UroToday.com) Detecting pre-clinical urothelial carcinoma (UC) using urinary comprehensive genomic profiling (uCGP) may providea valuable opportunity for early detection and screening of high-risk...
View ArticleIBCN 2023: Initial Results From The Prospective Randomized UroFollow Trial...
(UroToday.com) A growing body of evidence suggests that current follow-up strategies for patients with non-muscle invasive bladder cancer (NMIBC) result in overdiagnosis and may trigger overtreatment....
View ArticleIBCN 2023: Proteogenomic Characterization of Chemotherapy Response in Muscle...
(UroToday.com) To further understand the underlying mechanisms of neoadjuvant chemotherapy resistance and identify alternative treatments for neoadjuvant chemotherapy-resistant MIBCs, they performed...
View Article